IMGN Financial Facts

Clinical materials reimbursement: 1.2M
Total operating expenses: 47.33M
See Full Income Statement

Other long-term liabilities: 4.17M
Total liabilities and shareholders' equity: 222.35M
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date 8/4/16 EPS Growth Rate +45.1%
Average EPS % Beat Rate -33.9% Revenue Growth Rate +35.7%
Average % Move 1-Wk after EPS -10.6% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/4/16 Q416 N/A-$0.39 N/A N/A$17.11M N/A N/A N/A
4/29/16 Q316 -$0.37-$0.32 -$0.05$19.7M$23.02M N/A Details
1/29/16 Q216 -$0.38-$0.36 -$0.02N/A$17.87M N/A Details
10/27/15 Q116 -$0.39-$0.35 -$0.04$14.9M$15.84M N/A Details
7/31/15 Q415 -$0.71-$0.35 -$0.36$12.61M$15.42M N/A Details
4/24/15 Q315 -$0.25-$0.24 -$0.01$11.4M$20.95M N/A Details
1/30/15 Q215 $0.16-$0.05 +$0.21$48.3M$37.3M N/A Details
10/24/14 Q115 -$0.26-$0.15 -$0.11$13.2M$21.8M N/A Details